1 / 7

Alzheimer’s disease in a mere blood drop !

1. 1. Alzheimer’s disease in a mere blood drop !. Goals and business model. Developing blood biomarkers diagnosis solutions for neurodegenerative diseases Presently focused on Alzheimer’s disease Diagnostic kits Preclinical development of disease modifiers

raina
Download Presentation

Alzheimer’s disease in a mere blood drop !

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 1 1 Alzheimer’s disease in a mere blood drop ! Confidential JB/XR/IHD

  2. Goals and business model Developing blood biomarkers diagnosis solutions for neurodegenerative diseases Presently focused on Alzheimer’s disease Diagnostic kits Preclinical development of disease modifiers Stratification of clinical cohorts Development of screening tests Seeking partnerships in the future for Drug development throught biomarkers detection Manufacturing and distribution of diagnosis kits and dedicated devices 2 Confidential JB/XR/IHD

  3. Intellectual Property 5 patents, fully accepted, covering from the chemical synthesis of reagents to diagnosis applications Covered territory: Europe : published in France, Germany, United-Kingdom, Eire, Italia, Swiss. USA and Canada Israel Japan , Australia China, India, and Brazil 3 Confidential JB/XR/IHD

  4. Two biomarkers measured : PKC alteration as a functional biomarker b-amyloid binding as a specific biomarker Red blood cells are integrators of any biomarker alteration Limited life time meaning possibility of treatment’s monitoring 10 ml are enought to perform the assay, less than one drop Rationale 4 Confidential JB/XR/IHD

  5. 5 Applications of our peripheral biomarkers • These peripheral biomarkers are validated on : • in vitro models (cultured cell lines, primary neuronal cultures) • animal models (transgenic mice TASTPM , APP/PS1) • Human clinical trials Confidential JB/XR/IHD

  6. 6 Collaborative project with Pixcell Medical Technology , By matching the two technologies,creating the standard for the Point Of Care Diagnosis in Neurology in order ton diagnose and to follow the personalize patient’s treatment Confidential JB/XR/IHD

  7. 7 MARKET This device is first dedicated to the POC market : - Neurologists - Hospitals For the prupose of : - Initial Diagnosis - Treatment monitoring and companion test Confidential JB/XR/IHD

More Related